These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

• J0485

  Injection, belatacept, 1 mg

• J0490

  Injection, belimumab, 10 mg

• J0491

  Injection, anifrolumab-fnia, 1 mg

• J0500

  Injection, dicyclomine hcl, up to 20 mg

• J0515

  Injection, benztropine mesylate, per 1 mg

• J0517

  Injection, benralizumab, 1 mg

• J0520

  Injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg

• J0525

  Injection, cefotetan disodium, 10 mg

• J0528

  Injection, fosfomycin disodium, 20 mg

• J0558

  Injection, penicillin g benzathine and penicillin g procaine, 100,000 units

• J0561

  Injection, penicillin g benzathine, 100,000 units

• J0565

  Injection, bezlotoxumab, 10 mg

• J0567

  Injection, cerliponase alfa, 1 mg

• J0570

  Buprenorphine implant, 74.2 mg

• J0571

  Buprenorphine, oral, 1 mg

• J0572

  Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine

• J0573

  Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine

• J0574

  Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine

• J0575

  Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine

• J0576

  Injection, buprenorphine extended-release (brixadi), 1 mg

• J0577

  Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy

• J0578

  Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy

• J0582

  Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg

• J0583

  Injection, bivalirudin, 1 mg

• J0584

  Injection, burosumab-twza 1 mg

• J0585

  Injection, onabotulinumtoxina, 1 unit

• J0586

  Injection, abobotulinumtoxina, 5 units

• J0587

  Injection, rimabotulinumtoxinb, 100 units

• J0588

  Injection, incobotulinumtoxin a, 1 unit

• J0589

  Injection, daxibotulinumtoxina-lanm, 1 unit

• J0591

  Injection, deoxycholic acid, 1 mg

• J0592

  Injection, buprenorphine hydrochloride, 0.1 mg

• J0593

  Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)

• J0594

  injection, busulfan, 1 mg

• J0595

  Injection, butorphanol tartrate, 1 mg

• J0596

  Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units

• J0597

  Injection, c-1 esterase inhibitor (human), berinert, 10 units

• J0598

  Injection, c-1 esterase inhibitor (human), cinryze, 10 units

• J0599

  Injection, c-1 esterase inhibitor (human), (haegarda), 10 units

• J0600

  Injection, edetate calcium disodium, up to 1000 mg

• J0601

  Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)

• J0602

  Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)

• J0603

  Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)

• J0604

  Cinacalcet, oral, 1 mg, (for esrd on dialysis)

• J0605

  Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)

• J0606

  Injection, etelcalcetide, 0.1 mg

• J0607

  Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)

• J0608

  Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)

• J0609

  Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)

• J0610

  Injection, calcium gluconate (fresenius kabi), per 10 ml

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/21/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.